{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:07:34Z","timestamp":1790035654343,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Cytopathology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jasc.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:47:26Z","timestamp":1774658846000},"page":"331-339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Checkpoint kinase 1 protein as a diagnostic marker for pleural mesothelioma"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4462-9048","authenticated-orcid":false,"given":"Azadeh","family":"Asghari Birbaneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Meristoudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2700-2378","authenticated-orcid":false,"given":"Caspar","family":"Bundgaard Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-6710","authenticated-orcid":false,"given":"Weronika Maria","family":"Szejniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Derek Christian","family":"Leutscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3607-5640","authenticated-orcid":false,"given":"Vasiliki","family":"Panou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluf Dimitri","family":"R\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jasc.2026.03.004_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5644\/ama2006-124.335","article-title":"Update on diagnosing and reporting malignant pleural mesothelioma","volume":"50","author":"Savic","year":"2021","journal-title":"Acta Med Acad NLM (Medline)"},{"key":"10.1016\/j.jasc.2026.03.004_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jasc.2026.03.004_bib3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.5858\/arpa.2023-0304-RA","article-title":"Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 update of the consensus statement from the International Mesothelioma Interest Group","volume":"148","author":"Husain","year":"2024","journal-title":"Arch Pathol Lab Med Coll Am Pathol"},{"key":"10.1016\/j.jasc.2026.03.004_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/cyt.13055","article-title":"State-of-the-art cytology of pleural fluid, focusing on the diagnosis of mesothelioma","volume":"33","author":"Monaco","year":"2022","journal-title":"Cytopathology"},{"key":"10.1016\/j.jasc.2026.03.004_bib5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jasc.2026.03.004_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/20018525.2025.2580795","article-title":"Advances in diagnosis and management of pleural mesothelioma: the Danish Clinical Guidelines","volume":"12","author":"Panou","year":"2025","journal-title":"Eur Clin Respir J"},{"key":"10.1016\/j.jasc.2026.03.004_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2012.05.014","article-title":"Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: A review and update","volume":"44","author":"Ord\u00f3\u00f1ez","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jasc.2026.03.004_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jasc.2022.07.003","article-title":"Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma","volume":"11","author":"Lyngg\u00e5rd","year":"2022","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2026.03.004_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncy.22398","article-title":"Diagnostic mesothelioma biomarkers in effusion cytology","volume":"129","author":"Eccher","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2026.03.004_bib10","article-title":"Malignant pleural mesothelioma: an update","volume":"47","author":"Hajj","year":"2021","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.jasc.2026.03.004_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cncy.22509","article-title":"Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology","volume":"130","author":"Girolami","year":"2022","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2026.03.004_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10555-013-9429-5","article-title":"The detection and implication of genome instability in cancer","volume":"32","author":"Pikor","year":"2013","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jasc.2026.03.004_bib13","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","article-title":"Checkpoint kinase 1 in DNA damage response and cell cycle regulation","volume":"70","author":"Patil","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jasc.2026.03.004_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","article-title":"A new wave of innovations within the DNA damage response","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jasc.2026.03.004_bib16","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science (1979)"},{"key":"10.1016\/j.jasc.2026.03.004_bib17","article-title":"A subcellular map of the human proteome","volume":"356","author":"Thul","year":"2017","journal-title":"Science (1979)"},{"key":"10.1016\/j.jasc.2026.03.004_bib18","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2353\/ajpath.2009.080721","article-title":"Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis","volume":"174","author":"Romagnoli","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jasc.2026.03.004_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2009.03.016","article-title":"Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets","volume":"67","author":"R\u00f8e","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jasc.2026.03.004_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006554","article-title":"Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: The emerging gene portrait of the mesothelioma phenotype","volume":"4","author":"R\u00f8e","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jasc.2026.03.004_bib21","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/bjc.2014.576","article-title":"Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response","volume":"112","author":"Al-Kaabi","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jasc.2026.03.004_bib22","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.21037\/jtd.2017.10.158","article-title":"Overexpressed genes in malignant pleural mesothelioma: Implications in clinical management","volume":"10","author":"Barone","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jasc.2026.03.004_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040521","article-title":"Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma","volume":"7","author":"R\u00f8e","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jasc.2026.03.004_bib24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jasc.2026.03.004_bib25","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.5858\/arpa.2013-0610-CP","article-title":"Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center","volume":"138","author":"Fitzgibbons","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2026.03.004_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4143\/crt.2018.331","article-title":"Immunohistochemistry biomarkers predict survival in stage II\/III gastric cancer patients: From a prospective clinical trial","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jasc.2026.03.004_bib27","article-title":"STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jasc.2026.03.004_bib28","first-page":"1","article-title":"The clinical significance of CHEK1 in breast cancer: a high-throughput data analysis and immunohistochemical study","volume":"12","author":"Wu","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jasc.2026.03.004_bib29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jss.2013.12.016","article-title":"Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer","volume":"187","author":"Grabauskiene","year":"2014","journal-title":"J Surg Res"},{"key":"10.1016\/j.jasc.2026.03.004_bib30","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/0008-5472.CAN-16-3409","article-title":"CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib","volume":"77","author":"Sen","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jasc.2026.03.004_bib31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.28226","article-title":"Roles of Chk1 in cell biology and cancer therapy","volume":"134","author":"Zhang","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jasc.2026.03.004_bib32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.molonc.2011.07.002","article-title":"Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs","volume":"5","author":"Toledo","year":"2011","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jasc.2026.03.004_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jasc.2026.03.004_bib34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"De Reynies","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jasc.2026.03.004_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jasc.2026.03.004_bib36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/1878-0261.13591","article-title":"Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer","volume":"18","author":"Rigon","year":"2024","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jasc.2026.03.004_bib37","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","article-title":"ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1","volume":"21","author":"Zhao","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jasc.2026.03.004_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2013.10.005","article-title":"CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy","volume":"142","author":"McNeely","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jasc.2026.03.004_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/modpathol.2011.144","article-title":"Epithelial-mesenchymal transition in malignant mesothelioma","volume":"25","author":"Fassina","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jasc.2026.03.004_bib40","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jasc.2026.03.004_bib41","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.3390\/cimb44120398","article-title":"Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer","volume":"44","author":"Kim","year":"2022","journal-title":"Curr Issues Mol Biol"}],"container-title":["Journal of the American Society of Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294526000414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294526000414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:44:07Z","timestamp":1790034247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213294526000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2213294526000414"],"URL":"https:\/\/doi.org\/10.1016\/j.jasc.2026.03.004","relation":{},"ISSN":["2213-2945"],"issn-type":[{"value":"2213-2945","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Checkpoint kinase 1 protein as a diagnostic marker for pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Cytopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jasc.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society of Cytopathology.","name":"copyright","label":"Copyright"}]}}